The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
Von Willebrand Diseases
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
Phase 1/2 Study of VGA039 in Healthy Volunteers and Patients with Von Willebrand Disease (VIVID)
-
Orthopedic Institute for Children (UCLA), Los Angeles, California, United States, 90007
UC Davis Medical Center, Sacramento, California, United States, 95817
University of Colorado School of Medicine, Aurora, Colorado, United States, 80045
Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Atlanta, Georgia, United States, 30308
Hemophilia Center of Western PA, Pittsburgh, Pennsylvania, United States, 15213
Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232
University of Texas Southwestern, Dallas, Texas, United States, 75235
Washington Center for Bleeding Disorders, Seattle, Washington, United States, 98101
Versiti Comprehensive Center for Bleeding Disorders, Milwaukee, Wisconsin, United States, 53233
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to 60 Years
ALL
Yes
Vega Therapeutics, Inc,
2029-12